<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Addict Med</journal-id><journal-id journal-id-type="iso-abbrev">J Addict Med</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of addiction medicine</journal-title></journal-title-group><issn pub-type="ppub">1932-0620</issn><issn pub-type="epub">1935-3227</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11449257</article-id><article-id pub-id-type="pmcid-ver">PMC11449257.1</article-id><article-id pub-id-type="pmcaid">11449257</article-id><article-id pub-id-type="pmcaiid">11449257</article-id><article-id pub-id-type="manuscript-id">NIHMS1999957</article-id><article-id pub-id-type="pmid">39356620</article-id><article-id pub-id-type="doi">10.1097/ADM.0000000000001356</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1999957</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1999957</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Impact of High Potency Synthetic Opioids (HPSO) on Pharmacotherapies for Opioid Use Disorder: A Scoping Review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jegede</surname><given-names initials="O">Oluwole</given-names></name><degrees>M.D., M.P.H.</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>De Aquino</surname><given-names initials="JP">Joao P.</given-names></name><degrees>M.D.</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hsaio</surname><given-names initials="C">Connie</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Caldwell</surname><given-names initials="E">Ebony</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Funaro</surname><given-names initials="MC">Melissa C.</given-names></name><degrees>M.S.</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Petrakis</surname><given-names initials="I">Ismene</given-names></name><degrees>M.D.</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Muvvala</surname><given-names initials="SB">Srinivas B.</given-names></name><degrees>M.D., M.P.H.</degrees><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven CT</aff><aff id="A2"><label>2</label>Cushing/John Hay Whitney Medical Library, Yale University School of Medicine</aff><author-notes><corresp id="CR1"><bold>Corresponding Authors:</bold> Oluwole Jegede, M.D., M.P.H., 34 Park Street, New Haven CT 06519, <email>oluwole.jegede@yale.edu</email>; Joao P. De Aquino, MD, 950 Campbell Avenue, 151 West Haven CT 06516, <email>joao.deaquino@yale.edu</email></corresp><fn fn-type="equal" id="FN1"><label>*</label><p id="P1">O.J. and J.P.D. contributed equally to this work.</p></fn></author-notes><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2024</year></pub-date><pub-date pub-type="epub"><day>10</day><month>8</month><year>2024</year></pub-date><volume>18</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">472016</issue-id><fpage>499</fpage><lpage>510</lpage><pub-history><event event-type="nihms-submitted"><date><day>16</day><month>06</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>10</day><month>08</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-05 07:25:24.230"><day>05</day><month>10</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1999957.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P2">The clinical implications of high potency synthetic opioids (HPSO) on medications for opioid use disorder (MOUD) is not well understood. Although pharmacological interactions are plausible, the clinical significance of such interaction has not been systematically elucidated. This scoping review investigates the relationship between HPSO exposure and various MOUD treatment outcomes.</p></sec><sec id="S2"><title>Methods:</title><p id="P3">We followed PRISMA Extension for Scoping Reviews (PRISMA-ScR) for scoping reviews with extensive a priori search strategy of databases: MEDLINE, Embase, PsycInfo, Web of Science, CINAHL, and Cochrane.</p></sec><sec id="S3"><title>Results:</title><p id="P4">From 9,149 studies, 34 fulfilled the inclusion criteria. Synthesized data reveals several critical insights: First, there's a variable but high occurrence (38-80%) of HPSO usage among individuals on MOUD. Second, MOUDs are linked to a decreased risk of overdoses and deaths associated with HPSO. Third, HPSO consumption is correlated with the risk of precipitated withdrawal when starting buprenorphine. Fourth, low dose buprenorphine is being recognized as one method to avoid moderate withdrawal symptoms prior to treatment. Lastly, significant gaps exist in human experimental data concerning the effects of HPSO on key factors critical for treating OUD-craving, withdrawal symptoms, and pain.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P5">Current evidence supports MOUD safety and effectiveness in reducing non-medical opioid use. Further research is needed to explore HPSO&#8217;s influence on the acute factors preceding non-medical opioid use, such as cravings, withdrawal symptoms, and pain. This research could inform the optimization of MOUD dosing strategies. Achieving consensus and harmonizing data across clinical and research protocols could diminish variability, enhancing our understanding of HPSOs effect on MOUD treatment outcomes.</p></sec></abstract><kwd-group><kwd>Fentanyl</kwd><kwd>fentanyl analog</kwd><kwd>opioid pharmacotherapy</kwd><kwd>opioid addiction</kwd><kwd>treatment development</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>